Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round at RMB 200 million (USD 28.64 million), led by GF Qianhe Investment. Other investors included existing investors China Life Private Equity Investment, and Wuxi Xinshang Investment, alongside new investors LongRiver Investments, Sealand Innovation, and Guangdong Mintou Private Equity Fund. Proceeds will go towards clinical studies for multiple vaccine pipelines, human vaccine manufacturing base construction, and talent team expansion and improvement. The company has raised a total of RMB 800 million (USD 114.6 million) via two financing rounds this year.
Company Background and Technology Platforms
Founded in 2016, MaxHealth Bio boasts a world-leading new adjuvant platform, recombinant protein expression platform, and mRNA platform with a product pipeline consisting of preventative vaccines and therapeutic vaccines targeting hepatitis B virus (HBV), allergic diseases, and tumors. The company, with research and development centers in Chengdu, Shanghai, and Hangzhou, has two products in clinical stages.-Fineline Info & Tech
